Daehan Nupharm Co.,Ltd.
Financials
Valuation Metrics
Daehan Nupharm Co.,Ltd.'s Market Cap is ₩808B. At end of 2025 it was ₩943B. Ranked #1380 of 2,436 in KR market (top 57%), #774 of 1,649 on KOSDAQ (top 47%), #152 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 65%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 80.82B KRW | KR#1,380/2,436 Sec#152/234 |
| Revenue | 205.39B KRW | KR#1,001/2,436 Sec#56/234 |
| Net Income | 15.68B KRW | KR#733/2,436 Sec#49/234 |
| Total Assets | 275.89B KRW | KR#1,058/2,436 Sec#73/234 |
| Net Assets | 138.21B KRW | KR#1,165/2,436 Sec#88/234 |
| Employees | 397 | KR#610/2,436 Sec#52/234 |
| Value | ||
| P/E | 5.16x | KR#300/2,436 Sec#10/234 |
| P/B | 0.58x | KR#958/2,436 Sec#46/234 |
| PEG | 0.32x | KR#601/2,436 Sec#36/234 |
| P/S | 0.39x | KR#753/2,436 Sec#21/234 |
| EV/EBITDA | 25.93x | KR#1,140/2,436 Sec#71/234 |
| FCF Yield | -42.74% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 11.34% | KR#421/2,436 Sec#27/234 |
| ROA | 5.68% | KR#572/2,436 Sec#43/234 |
| Op. Margin | 5.17% | KR#910/2,436 Sec#74/234 |
| Revenue Growth | 5.76% | KR#1,130/2,436 Sec#104/234 |
| Earnings Growth | 16.28% | KR#778/2,436 Sec#49/234 |
| Financial Health | ||
| Debt Ratio | 199.62% | KR#1,713/2,436 Sec#191/234 |
| Total Debt | 213.38B KRW | KR#470/2,436 Sec#24/234 |
| FCF | -34.54B KRW | KR#2,026/2,436 Sec#198/234 |
| Cash | 18.94B KRW | KR#1,266/2,436 Sec#93/234 |
| Current Ratio | 1.57x | KR#1,257/2,436 Sec#137/234 |
| Net Debt/EBITDA | 18.31x | KR#1,413/2,436 Sec#99/234 |
| Dividend | ||
| Div. Yield | 1.81% | KR#941/2,436 Sec#50/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -20.48% | KR#1,280/2,436 Sec#106/234 |
| 1M Return | 1.44% | KR#737/2,436 Sec#65/234 |
| From 52W High | -28.73% | KR#370/2,436 Sec#24/234 |
| 1Y MDD | -35.08% | KR#348/2,436 Sec#23/234 |
| Trading | ||
| Volume | 19,645 shares | KR#1,851/2,436 Sec#185/234 |
| Foreign Own. | 0.55% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 1,092 KRW | KR#594/2,436 Sec#42/234 |
| BPS | 9,847 KRW | KR#950/2,436 Sec#67/234 |
Company Info
Established in 1984 and listed on KOSDAQ in 2002, Daehan Newpharm is a pharmaceutical company headquartered in Hwaseong-si, Gyeonggi-do. It focuses on specialty pharmaceuticals for metabolic diseases like hypertension and diabetes, as well as digestive ulcer treatments, while strengthening non-reimbursable products such as obesity treatments, vitamins, and immune enhancers. The company diversifies into animal pharmaceuticals, developing pet products and farm environment improvers, and expands its bio business into stem cell-based anti-aging agents and cell therapies.